Sellas Will Take Increasingly Good Results With NeuVax Into FDA Discussions
Executive Summary
Preparing to meet with FDA in December to plan next steps for NeuVax in triple-negative breast cancer, Sellas reveals 26-month data that show further clinical benefit compared with a 19-month interim look. Firm still hopes to out-license the vaccine candidate.
You may also be interested in...
Phase II Study Opens Window For Sellas' NeuVax In Triple-Negative Breast Cancer
Sellas is pursuing accelerated approval for NeuVax in triple-negative breast cancer based on Phase II data, but that may be a tough sell with the FDA.
Galena Left To Hope Review Of Trial Operations Rescues NeuVax
Cancer vaccine development is a tricky undertaking, but Galena may be grasping at last straws with a third-party review of a recently halted study of NeuVax, hoping to discover operational reasons for cancer vaccine's poor performance.
Asia Deal Watch: Taiho Brings Cullinan Pearl Back In House
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.